We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+12.67%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$701M
AUM Growth
+$112M
Cap. Flow
+$22.9M
Cap. Flow %
3.26%
Top 10 Hldgs %
45.26%
Holding
159
New
30
Increased
40
Reduced
26
Closed
28

Sector Composition

Rank Sector Weight
1 Healthcare 65.28%
2 Miscellaneous 21.58%
3 Technology 5.67%
4 Communication Services 4.68%
5 Industrials 1.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ICPT
151
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
-30,000
Closed -$3.63M
BLCM
152
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
-25,000
Closed -$2.92M
ENDP
153
DELISTED
Endo International plc
ENDP
-240,000
Closed -$2.68M
XLRN
154
DELISTED
Acceleron Pharma
XLRN
-35,000
Closed -$1.06M
ALXN
155
DELISTED
Alexion Pharmaceuticals
ALXN
-100,000
Closed -$12.2M
AKAO
156
DELISTED
Achaogen Inc
AKAO
-75,000
Closed -$1.63M
CELG
157
CALL
DELISTED
Celgene Corp
CELG
-500
Closed -$6.77M
NDRM
158
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
-74,500
Closed -$2.23M

Similar funds

Sphera Funds Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sphera Funds Management held 159 positions worth $701M, up 19% from $589M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management deployed $22.9M of net new capital in Q3 2017, opening 30 new positions and adding to 40 existing holdings. Its largest new stake was Cellcom Israel, Ltd.: 1,535,988 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 68% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Caesarstone, an estimated $3.28M trimmed.

  • Sphera Funds Management's largest Q3 2017 buy was Cellcom Israel, Ltd.: 1,535,988 shares worth $14.3M.
  • Sphera Funds Management added most to Merck in Q3 2017, an estimated $6.67M increase.
  • Sphera Funds Management's biggest Q3 2017 reduction was Caesarstone, cutting an estimated $3.28M.
  • Sphera Funds Management fully exited Novartis in Q3 2017, selling an estimated $16M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $701M portfolio in Q3 2017.
  • Sphera Funds Management opened 30 new positions and closed 28 in Q3 2017.
  • Sphera Funds Management's portfolio value rose 19% quarter-over-quarter to $701M.

Based on Sphera Funds Management's 13F filing for Q3 2017, filed 9 Nov 2017.